X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27) 27
male (24) 24
female (22) 22
aged (20) 20
index medicus (19) 19
cardiac & cardiovascular systems (18) 18
aged, 80 and over (13) 13
aortic stenosis (12) 12
outcomes (11) 11
middle aged (10) 10
mortality (10) 10
risk factors (10) 10
aortic valve stenosis - surgery (9) 9
patients (9) 9
replacement (9) 9
stenosis (9) 9
treatment outcome (9) 9
implantation (8) 8
transcatheter aortic valve implantation (8) 8
abridged index medicus (7) 7
aorta (7) 7
stents (7) 7
poland - epidemiology (6) 6
single-center (6) 6
time factors (6) 6
aortic valve (5) 5
drug therapy, combination (5) 5
elderly (5) 5
quality of life (5) 5
registry (5) 5
risk (5) 5
surgery (5) 5
transcatheter aortic valve replacement - adverse effects (5) 5
aortic valve - surgery (4) 4
aortic valve stenosis (4) 4
aortic valve stenosis - mortality (4) 4
cardiology (4) 4
cardiovascular (4) 4
double-blind method (4) 4
elderly-patients (4) 4
health aspects (4) 4
high-risk patients (4) 4
impact (4) 4
intervention (4) 4
ischemia (4) 4
metaanalysis (4) 4
percutaneous coronary intervention (4) 4
platelet aggregation inhibitors - adverse effects (4) 4
platelet aggregation inhibitors - therapeutic use (4) 4
prospective studies (4) 4
quality-of-life (4) 4
risk assessment (4) 4
tavi (4) 4
thrombosis (4) 4
transcatheter aortic valve replacement - methods (4) 4
adult (3) 3
aortic valve stenosis - diagnosis (3) 3
bleeding (3) 3
care and treatment (3) 3
clopidogrel (3) 3
complications (3) 3
dosage and administration (3) 3
drug-eluting stents (3) 3
heart (3) 3
heart attacks (3) 3
hemorrhage - chemically induced (3) 3
improvement (3) 3
incidence (3) 3
multicenter (3) 3
postoperative complications - epidemiology (3) 3
predictors (3) 3
primary pci (3) 3
severity of illness index (3) 3
transcatheter aortic valve replacement - mortality (3) 3
acs (2) 2
acute coronary syndromes (2) 2
adenosine monophosphate - adverse effects (2) 2
adenosine monophosphate - analogs & derivatives (2) 2
adenosine monophosphate - therapeutic use (2) 2
aggregation (2) 2
american-college (2) 2
analysis (2) 2
angioplasty (2) 2
angioplasty, balloon, coronary - adverse effects (2) 2
antiplatelet therapy (2) 2
aortic valve - diagnostic imaging (2) 2
aortic valve stenosis - diagnostic imaging (2) 2
aortic valve stenosis - therapy (2) 2
aspirin - administration & dosage (2) 2
aspirin - adverse effects (2) 2
aspirin - therapeutic use (2) 2
balloon valvuloplasty - adverse effects (2) 2
bare metal (2) 2
bentall de bono (2) 2
bleedings (2) 2
blood platelets (2) 2
cabg (2) 2
cardiac patients (2) 2
cardiac-surgery (2) 2
catheters (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2017, Volume 69, Issue 2, pp. 176 - 185
Abstract Background Cangrelor, an intravenous, reversible P2Y12 antagonist, is approved for use in patients undergoing percutaneous coronary intervention... 
Cardiovascular | Internal Medicine | coronary artery disease | bleeding | antiplatelet therapy | outcomes | CARDIAC & CARDIOVASCULAR SYSTEMS | PRIMARY PCI | BIVALIRUDIN | IMPAIRED BIOAVAILABILITY | CHAMPION PHOENIX | CLOPIDOGREL | PLATELET INHIBITION | BLOOD-TRANSFUSION | ELEVATION MYOCARDIAL-INFARCTION | INSIGHTS | Prospective Studies | Ticlopidine - therapeutic use | Humans | Middle Aged | Male | Aspirin - adverse effects | Ticlopidine - adverse effects | Female | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Double-Blind Method | Angioplasty, Balloon, Coronary - methods | Myocardial Ischemia - prevention & control | Treatment Outcome | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Adenosine Monophosphate - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Infusions, Intravenous | Cohort Studies | Transluminal angioplasty | Continuing medical education | Cardiac patients | Medical care | Research institutes | Cardiology | Quality management | Heart attacks | Mortality | Thrombosis | Patients | Studies | Consortia | Ischemia | Coronary vessels | Bailouts | Intubation | Acute coronary syndromes | Stents | Drug dosages | Veins & arteries
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1303 - 1313
This clinical trial compared two antiplatelet regimens during PCI: oral clopidogrel and intravenous cangrelor. As compared with clopidogrel, cangrelor resulted... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | METAANALYSIS | TICAGRELOR | CARDIOVASCULAR EVENTS | ACHIEVE OPTIMAL MANAGEMENT | CLOPIDOGREL PRETREATMENT | PRASUGREL | STANDARD THERAPY | ANTIPLATELET THERAPY | STRATEGIES | Double-Blind Method | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Adenosine Monophosphate - analogs & derivatives | Hemorrhage - etiology | Intention to Treat Analysis | Myocardial Ischemia - therapy | Ticlopidine - adverse effects | Female | Aged | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Stents - adverse effects | Thrombosis - mortality | Platelet Aggregation Inhibitors - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Cangrelor | Angioplasty | Patient outcomes | Product/Service Evaluations | Hemorrhage | Risk factors | Control | Ischemia | Dosage and administration | Drug therapy | Myocardial infarction | Adenosine | Heart attacks | Intravenous administration | Thrombosis | Patients | Bleeding | Dyspnea | Implants | Clopidogrel | Acute coronary syndromes | Respiration
Journal Article
International Heart Journal, ISSN 1349-2365, 2017, Volume 58, Issue 1, pp. 50 - 55
Blood transfusions are considered as an important predictor of adverse outcome in patients with severe aortic (AS) undergoing transcatheter aortic valve... 
Aortic stenosis | Elderly | Outcomes | Bleedings | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | RESEARCH CONSORTIUM DEFINITIONS | TAVI | RISK | SINGLE-CENTER | PREVALENCE | REPLACEMENT | PREDICTORS | COMPLICATIONS | CLINICAL-OUTCOMES | Blood transfusions | Mortality | Blood cells | Erythrocytes | Aorta | Aortic valve | Blood transfusion | Patients
Journal Article
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 11, pp. 1113 - 1121
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 2015, Volume 8, Issue 12, pp. 1552 - 1562
Journal Article
Postepy w Kardiologii Interwencyjnej, ISSN 1734-9338, 03/2016, Volume 12, Issue 2, pp. 122 - 127
Transcatheter aortic valve implantation (TAVI) is a less invasive treatment option for elderly, high-risk patients with symptomatic severe aortic stenosis (AS)... 
Aortic stenosis | Transcatheter aortic valve implantation | High-risk patients | Registry | Outcomes | transcatheter aortic valve implantation | Original Paper | registry | aortic stenosis | outcomes | high-risk patients
Journal Article
Journal Article